The size of the Asia-Pacific Cancer Vaccines Market is predicted to value USD 0.74 billion in 2022 and is estimated to reach USD 1.72 billion by the end of 2027, growing at a CAGR of 18.24% between 2022 to 2027.
The rising number of cancer patients and the growing awareness of the benefits of vaccines are majorly driving the APAC cancer vaccines market. The increasing occurrence of different types of cancer and technological advancements in the healthcare field is expected to drive market growth. Market players in the region are introducing advanced vaccines to increase the product demand is most likely to uplift the market growth. The other factors, such as increasing research and development activities and a growing number of start-ups and biotech companies across the region, are projected to propel the market growth. Growing Incidences of human papillomavirus infections, implementation of prophylactic cancer vaccines, rising government support and heavy investments in developing cancer vaccines, the launch of new cancer vaccines, and continuous developments in cancer vaccines are all expected to drive up demand for cancer vaccines over the forecast period. However, Increased usage of tobacco products and alcohol consumption, along with an unhealthy diet and lack of physical activity, are the main cancer risk factors prevalent in APAC. According to a post by WHO, Cancer is a leading cause of death and is expected to rise by about 70% over the next two decades. Prostrate, cervical, lung, and breast cancers are common forms with fewer diagnostic and therapeutic techniques commercialized for the treatment. The rise in awareness among the people about cancer therapy and the growing geriatric population in emerging countries such as China and India will most likely augment the APAC regional market growth.
In addition, increasing investment and funding by the government and private organizations to develop new vaccines accelerate the market growth. However, increasing healthcare expenditure and healthcare infrastructure, adoption of preventive and therapeutic vaccines are the factors majorly contributing to the market growth.
However, advances in manufacturing technology and the time-consuming procedure of developing a single cancer vaccine are projected to stifle market growth during the forecast period.
This research report on the APAC cancer vaccines market has been segmented and sub-segmented into the following categories:
By Cancer Type:
By Vaccine Type:
By End User:
By Country:
The Asia Pacific cancer vaccines market is expected to account for a substantial share of the global cancer vaccine market during the forecast period. The market growth is attributed to the high growing prevalence of cancer and contagious diseases and government initiatives for creating awareness about cancer treatment. Moreover, investments by the government and non-government organizations for the new vaccine development are boosting the market growth. As a result, the countries such as India, China, and Japan are majorly witnessing significant market revenue during the forecast period. However, in APAC regional market growth, China dominated the cancer vaccines market growth over the forecast period, technological advancements in medical sectors, and increasing medical tourism for creating awareness about cancer therapies are upsurging the market growth in the country. On the other hand, the Indian cancer vaccines market is anticipated to contribute to the APAC regional market growth. The increasing number of hospitals treating cancer patients, support from the government for conducting the research and development activities, and improving the healthcare infrastructure are likely driving the market growth.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the APAC cancer vaccines market profiled in this report are Dendreon, GlaxoSmithKline, and Merck. In addition, companies with their products in the pipeline are Aduro Biotech, Advantage, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, and Vaxon Biotech.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology Data
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment type
5.1.1 Prophylactic
5.1.2 Therapeutic
5.1.3 Y-o-Y Growth Analysis, By Cancer Type
5.1.4 Market Attractiveness Analysis, By Cancer type
5.1.5 Market Share Analysis, By Cancer Type
5.2 Cancer Type
5.2.1 Introduction
5.2.2 Prostate Cancer
5.2.3 Cervical Cancer
5.2.4 Colorectal Cancer
5.2.5 Throat Cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Cancer Type
5.2.8 Market Attractiveness Analysis, By Cancer type
5.2.9 Market Share Analysis, By Cancer Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Tumour cell Vaccines
5.3.3 Protein or Peptide Vaccines
5.3.4 Genetic Vaccines
5.3.4.1 DNA Vaccines
5.3.4.2 RNA Vaccines
5.3.5 Dendritic cell Vaccines
5.3.6 other Vaccines
5.3.7 Y-o-Y Growth Analysis, By Vaccine Type
5.3.8 Market Attractiveness Analysis, By Vaccine Type
5.3.9 Market Share Analysis, By Vaccine Type
5.4 End Users
5.4.1 Introduction
5.4.2 Cancer Treatment Centers
5.4.3 Research Institutes
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment Type
6.1.3.3 By Cancer Type
6.1.3.4 By Vaccine Type
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment Type
6.1.4.3 By Cancer Type
6.1.4.4 By Vaccine Type
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment Type
6.1.5.3 By Cancer Type
6.1.5.4 By Vaccine Type
6.1.5.5 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & co
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dendreon
8.3 Glaxosmithkline
8.4 AstraZeneca plc
8.5 Aduro BioTech
8.6 MedImmune
8.7 Sanofi
8.8 Galena Biopharma
8.9 Ubivac
8.10 Oxford Biomedica
8.11 Immunofrontier Inc
8.12 Oncovir Inc
8.13 Immune Cell Therapy (ICT)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
